{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:02:17Z","timestamp":1790744537774,"version":"4.1.0"},"reference-count":137,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.<\/jats:p>","DOI":"10.3390\/ijms21093272","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T03:10:38Z","timestamp":1588821038000},"page":"3272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":204,"title":["Combination Drug Therapy for the Management of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-8587","authenticated-orcid":false,"given":"Md. Tanvir","family":"Kabir","sequence":"first","affiliation":[{"name":"Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-7840","authenticated-orcid":false,"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka 1213, Bangladesh"},{"name":"Pharmakon Neuroscience Research Network, Dhaka 1207, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8774-5616","authenticated-orcid":false,"given":"Abdullah Al","family":"Mamun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka 1213, Bangladesh"},{"name":"Pharmakon Neuroscience Research Network, Dhaka 1207, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-4871","authenticated-orcid":false,"given":"Philippe","family":"Jeandet","sequence":"additional","affiliation":[{"name":"Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, P.O. Box 1039, 51687 Reims CEDEX 2, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Aleya","sequence":"additional","affiliation":[{"name":"Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comt\u00e9 University, F-25030 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha A.","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-2078","authenticated-orcid":false,"given":"Ghulam Md","family":"Ashraf","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia"},{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[{"name":"Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3017-9924","authenticated-orcid":false,"given":"May N.","family":"Bin-Jumah","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11474, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-2713","authenticated-orcid":false,"given":"Mohamed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[{"name":"Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia"},{"name":"Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., Al Mamun, A., Jakaria, M., Thangapandiyan, S., Ahmad, J., Rahman, M.A., Mathew, B., Abdel-Daim, M.M., and Aleya, L. (2019). Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci. Total Environ., 135624.","DOI":"10.1016\/j.scitotenv.2019.135624"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Al Mamun, A., and Uddin, M.S. (2020). KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor to Abate Alzheimer\u2019s Disease. Comb. Chem. High Throughput Screen., 23.","DOI":"10.2174\/1386207323666200117103144"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2016). 2016 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 12, 459\u2013509.","DOI":"10.1016\/j.jalz.2016.03.001"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2019.00197","article-title":"Emerging Signal Regulating Potential of Genistein Against Alzheimer\u2019s Disease: A Promising Molecule of Interest","volume":"7","author":"Uddin","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11910-014-0499-8","article-title":"Dominantly Inherited Alzheimer Network Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies","volume":"14","author":"Ringman","year":"2014","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","article-title":"APOE and Alzheimer\u2019s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer\u2019s Pathogenesis","volume":"56","author":"Uddin","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_7","first-page":"1","article-title":"Autosomal-dominant Alzheimer\u2019s disease: A review and proposal for the prevention of Alzheimer\u2019s disease","volume":"2","author":"Bateman","year":"2011","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., Kabir, M.T., Niaz, K., Jeandet, P., Cl\u00e9ment, C., Mathew, B., Rauf, A., Rengasamy, K.R.R., Sobarzo-S\u00e1nchez, E., and Ashraf, G.M. (2020). Molecular insight into the therapeutic promise of flavonoids against Alzheimer\u2019s disease. Molecules, 25.","DOI":"10.3390\/molecules25061267"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1381612826666200107142541","article-title":"Emerging Potential of Naturally Occurring Autophagy Modulator against Neurodegeneration","volume":"26","author":"Rahman","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101046","DOI":"10.1016\/j.arr.2020.101046","article-title":"Circadian and sleep dysfunction in Alzheimer\u2019s disease","volume":"60","author":"Uddin","year":"2020","journal-title":"Ageing Res. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.4103\/1673-5374.274329","article-title":"Toxic tau: Structural origins of tau aggregation in Alzheimer\u2019s disease","volume":"15","author":"Mamun","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., Kabir, M.T., Rahman, M.M., Mathew, B., Shah, M.A., and Ashraf, G.M. (2020). TV 3326 for Alzheimer\u2019s dementia: A novel multimodal ChE and MAO inhibitors to mitigate Alzheimer\u2019s-like neuropathology. J. Pharm. Pharmacol.","DOI":"10.1111\/jphp.13244"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000481812","article-title":"Spectrum of Disease and Prescription Pattern for Outpatients with Neurological Disorders: An Empirical Pilot Study in Bangladesh","volume":"25","author":"Uddin","year":"2018","journal-title":"Ann. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: The path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers. Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/1381612825666191011102444","article-title":"NMDA Receptor Antagonists: Repositioning of Memantine as Multitargeting Agent for Alzheimer\u2019s Therapy","volume":"25","author":"Kabir","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scitotenv.2019.134836","article-title":"Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer\u2019s disease","volume":"700","author":"Uddin","year":"2020","journal-title":"Sci. Total Environ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.2174\/1381612825666191008103141","article-title":"Cholinesterase Inhibitors for Alzheimer\u2019s Disease: Multitargeting Strategy based on Anti-Alzheimer\u2019s Drugs Repositioning","volume":"25","author":"Kabir","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2147\/DDDT.S86463","article-title":"A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease","volume":"10","author":"Deardorff","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopha.2018.06.147","article-title":"A molecular approach in drug development for Alzheimer\u2019s disease","volume":"106","author":"Kettle","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Capurro, V., Busquet, P., Lopes, J.P., Bertorelli, R., Tarozzo, G., Bolognesi, M.L., Piomelli, D., Reggiani, A., and Cavalli, A. (2013). Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer\u2019s Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056870"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","article-title":"Combination Therapy for Alzheimer\u02bcs Disease","volume":"28","author":"Patel","year":"2011","journal-title":"Drugs Aging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/00023210-200418130-00001","article-title":"Combination therapy in Alzheimer\u2019s disease: A review of current evidence","volume":"18","author":"Schmitt","year":"2004","journal-title":"CNS Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","article-title":"Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease","volume":"22","author":"Atri","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1185\/03007995.2011.582484","article-title":"Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer\u2019s disease: A multicenter, randomized, open-label, parallel-group study","volume":"27","author":"Choi","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/01.wnl.0000223333.42368.f1","article-title":"Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment","volume":"67","author":"Cummings","year":"2006","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1185\/03007990903434914","article-title":"A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer\u2019s disease: A post hoc analysis","volume":"26","author":"Farlow","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1368-5031.2005.00769.x","article-title":"Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer\u2019s disease who failed to benefit from previous cholinesterase inhibitor treatment","volume":"60","author":"Dantoine","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/01.wad.0000213859.35355.59","article-title":"Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment","volume":"20","author":"Feldman","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","article-title":"Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease","volume":"80","author":"Lopez","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/156720508783884576","article-title":"Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"5","author":"Porsteinsson","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.wad.0000213860.35355.d4","article-title":"Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis","volume":"20","author":"Schmitt","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000100875","article-title":"Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer\u2019s Disease Treated with Rivastigmine","volume":"23","author":"Riepe","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jalz.2010.09.003","article-title":"Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer\u2019s disease","volume":"7","author":"Weiner","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/gps.2788","article-title":"A review of the effects of memantine on clinical progression in Alzheimer\u2019s disease","volume":"27","author":"Wilkinson","year":"2012","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"T793","DOI":"10.1016\/j.jalz.2008.05.2476","article-title":"P4-405: A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer\u2019s disease","volume":"4","author":"Grossberg","year":"2008","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_39","first-page":"367","article-title":"Memantine: A review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias","volume":"4","author":"Thomas","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer\u2019s Disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/1570159X11311030005","article-title":"Nicotinic Receptors in Neurodegeneration","volume":"11","author":"Posadas","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2174\/138945012800399026","article-title":"\u03b17 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson\u2019s disease","volume":"13","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2006.04.007","article-title":"Acetylcholinesterase inhibitors used in treatment of Alzheimer\u2019s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade","volume":"51","author":"Kume","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/brb3.118","article-title":"Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity","volume":"3","author":"Lopes","year":"2013","journal-title":"Brain Behav."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1021\/jm800577j","article-title":"Inhibition of Acetylcholinesterase, \u03b2-Amyloid Aggregation, and NMDA Receptors in Alzheimer\u2019s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush","volume":"51","author":"Rosini","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1021\/jm3009458","article-title":"Combining Galantamine and Memantine in Multitargeted, New Chemical Entities Potentially Useful in Alzheimer\u2019s Disease","volume":"55","author":"Simoni","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","article-title":"Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond","volume":"5","author":"Lipton","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/364626a0","article-title":"A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds","volume":"364","author":"Lipton","year":"1993","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/ph7020113","article-title":"From single target to multitarget\/network therapeutics in Alzheimer\u2019s therapy","volume":"7","author":"Zheng","year":"2014","journal-title":"Pharmaceuticals"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/brain\/awq056","article-title":"Beneficial effect of human anti-amyloid-\u03b2 active immunization on neurite morphology and tau pathology","volume":"133","author":"William","year":"2010","journal-title":"Brain"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E2518-27","DOI":"10.1073\/pnas.1306832110","article-title":"A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss","volume":"110","author":"Talantova","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/cmdc.201600014","article-title":"Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer\u2032s Disease","volume":"11","author":"Prati","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0006-8993(99)02096-X","article-title":"Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer\u2019s diseased brains","volume":"852","author":"Suh","year":"2000","journal-title":"Brain Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20466","DOI":"10.1074\/jbc.M100175200","article-title":"Alzheimer\u2019s Disease Amyloid-\u03b2 Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits","volume":"276","author":"Curtain","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1021\/jm100329q","article-title":"Novel Tacrine\u22128-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer\u2019s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties","volume":"53","author":"Conde","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14728222.2016.1121237","article-title":"Changing paradigm to target microglia in neurodegenerative diseases: From anti-inflammatory strategy to active immunomodulation","volume":"20","author":"Prati","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Weinstock, M., Bejar, C., Wang, R.-H., Poltyrev, T., Gross, A., Finberg, J.P.M., and Youdim, M.B.H. (2000). TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease. Advances in Research on Neurodegeneration, Springer.","DOI":"10.1007\/978-3-7091-6301-6_10"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-008-9139-6","article-title":"The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats","volume":"37","author":"Weinreb","year":"2009","journal-title":"J. Mol. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1471-4159.2004.02425.x","article-title":"Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo","volume":"89","author":"Amit","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2010-1390","article-title":"PBT2 rapidly improves cognition in alzheimer\u2019s disease: Additional phase II analyses","volume":"20","author":"Faux","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1021\/ar500152x","article-title":"The ongoing search for small molecules to study metal-Associated amyloid-\u03b2 species in alzheimers disease","volume":"47","author":"Savelieff","year":"2014","journal-title":"Acc. Chem. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1471-4159.2005.03341.x","article-title":"Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion","volume":"95","author":"Gal","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","article-title":"Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition","volume":"95","author":"Zheng","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12035-012-8304-7","article-title":"Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer\u2019s-like neuropathology and age-related alterations in mice","volume":"46","author":"Kupershmidt","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.mad.2012.03.001","article-title":"Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice","volume":"133","author":"Kupershmidt","year":"2012","journal-title":"Mech. Ageing Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"1C-PiB PET assessment of change in fi brillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/hv.28183","article-title":"Vaccination against Alzheimer disease: An update on future strategies","volume":"10","author":"Fettelschoss","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b242 immunisation in Alzheimer\u2019s disease: Follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.intimp.2009.10.005","article-title":"Antibody concentrations to A\u03b21-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations","volume":"10","author":"Klaver","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"ref_76","unstructured":"ClinicalTrials.gov (2020, March 19). A Study of Semagacestat for Alzheimer\u2019s Patients (Identity XT), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01035138."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid \u03b2 production with a \u03b3-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656560903044982","article-title":"Development of semagacestat (LY450139), a functional \u03b3-secretase inhibitor, for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Henley","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - A randomized, double-blind, placebo-controlled, multi-centre study (the alphase study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: Exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study","volume":"8","author":"Vellas","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer\u2019s disease: A randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1476-5381.2009.00249.x","article-title":"5-HT 1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception","volume":"158","author":"Martel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_91","unstructured":"ClinicalTrials.gov (2020, March 19). Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer\u2019s Type, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00104013."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.wnl.0000335163.88054.e7","article-title":"Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial","volume":"71","author":"Sevigny","year":"2008","journal-title":"Neurology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/156720511796391863","article-title":"Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil","volume":"8","author":"Alvarez","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/JGP.0b013e3181aad585","article-title":"Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study","volume":"17","author":"Mohs","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for Alzheimer\u2019s disease: A phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2009.09.022","article-title":"Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2","volume":"288","author":"Plastino","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1212\/WNL.60.1.148-a","article-title":"No additional benefit of HRT on response to rivastigmine in menopausal women with AD","volume":"60","author":"Rigaud","year":"2003","journal-title":"Neurology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer\u2019s Disease","volume":"336","author":"Sano","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/archneur.63.10.1402","article-title":"\u03c9-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial","volume":"63","author":"Cederholm","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096588","article-title":"Long-term efficacy and safety of celecoxib in Alzheimer\u2019s disease","volume":"23","author":"Soininen","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial","volume":"289","author":"Aisen","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jmb.2019.01.018","article-title":"Metal Toxicity Links to Alzheimer\u2019s Disease and Neuroinflammation","volume":"431","author":"Huat","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13530-018-0340-x","article-title":"Pathogenic mechanisms of heavy metal induced-Alzheimer\u2019s disease","volume":"10","author":"Lee","year":"2018","journal-title":"Toxicol. Environ. Health Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2018.01.001","article-title":"Complex noradrenergic dysfunction in Alzheimer\u2019s disease: Low norepinephrine input is not always to blame","volume":"1702","author":"Gannon","year":"2019","journal-title":"Brain Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnins.2015.00220","article-title":"Noradrenergic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Gannon","year":"2015","journal-title":"Front. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neurobiolaging.2006.02.012","article-title":"Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease","volume":"28","author":"Cacabelos","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/156720507781788855","article-title":"Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly","volume":"4","author":"Mufson","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1601-183X.2007.00378.x","article-title":"Neurotrophic factors in Alzheimer\u2019s disease: Role of axonal transport","volume":"Volume 7","author":"Schindowski","year":"2008","journal-title":"Proceedings of the Genes, Brain and Behavior"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"136","DOI":"10.6000\/1927-5951.2017.07.03.10","article-title":"Inspection of phytochemical content and in vitro antioxidant profile of Gnaphalium luteoalbum L.: An unexplored phytomedicine","volume":"7","author":"Uddin","year":"2017","journal-title":"J. Pharm. Nutr. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.13005\/bpj\/1229","article-title":"In vitro screening for phytochemicals and antioxidant activities of Syngonium podophyllum l.: An incredible therapeutic plant","volume":"10","author":"Hossain","year":"2017","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4103\/1995-7645.237189","article-title":"Phytochemical analysis and antioxidant profile of methanolic extract of seed, pulp and peel of Baccaurea ramiflora Lour","volume":"11","author":"Uddin","year":"2018","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.6000\/1927-5951.2018.08.03.6","article-title":"Phytochemical screening and antioxidant profile of Syngonium podophyllum schott stems: A fecund phytopharmakon","volume":"8","author":"Uddin","year":"2018","journal-title":"J. Pharm. Nutr. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., and Kabir, M.T. (2019). Oxidative Stress in Alzheimer\u2019s Disease: Molecular Hallmarks of Underlying Vulnerability. Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease, Springer Singapore.","DOI":"10.1007\/978-981-13-9636-6_5"},{"key":"ref_118","unstructured":"Uddin, M.S., and Upaganlawar, A.B. (2019). Oxidative Stress and Antioxidant Defense: Biomedical Value in Health and Diseases, Nova Science Publishers."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"50","DOI":"10.6000\/2292-2598.2017.05.02.3","article-title":"In vitro screening for antioxidant and anticholinesterase effects of Uvaria littoralis Blume.: A nootropic phytotherapeutic remedy","volume":"5","author":"Rahman","year":"2017","journal-title":"J. Intellect. Disabil. Diagnosis Treat."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/ARRB\/2017\/35692","article-title":"In vivo screening for analgesic and anti-inflammatory activities of Syngonium podophyllum L.: A remarkable herbal medicine","volume":"16","author":"Hossain","year":"2017","journal-title":"Annu. Res. Rev. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/1562038","article-title":"Ethnopharmacological Inspections of Organic Extract of Oroxylum indicum in Rat Models: A Promising Natural Gift","volume":"2019","author":"Begum","year":"2019","journal-title":"Evidence-Based Complement. Altern. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/ph3061812","article-title":"Non-steroidal anti-inflammatory drugs in alzheimer\u2019s disease and parkinson\u2019s disease: Reconsidering the role of neuroinflammation","volume":"3","author":"Moore","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.2010.03830.x","article-title":"Diabetes mellitus and Alzheimer\u2019s disease: Shared pathology and treatment?","volume":"71","author":"Akter","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s11011-018-0227-1","article-title":"New views and possibilities of antidiabetic drugs in treating and\/or preventing mild cognitive impairment and Alzheimer\u2019s Disease","volume":"33","author":"Zhong","year":"2018","journal-title":"Metab. Brain Dis."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Chow, V.W., Savonenko, A.V., Melnikova, T., Kim, H., Price, D.L., Li, T., and Wong, P.C. (2010). Modeling an anti-amyloid combination therapy for Alzheimer\u2019s disease. Sci. Transl. Med., 2.","DOI":"10.1126\/scitranslmed.3000337"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2010.538083","article-title":"WFSBP Task Force on Treatment Guidelines for Alzheimer\u2019s Disease and other Dementias World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer\u2019s disease and other dementias","volume":"12","author":"Ihl","year":"2011","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_127","first-page":"57","article-title":"Treatment of Alzheimer\u2019s disease: The role of symptomatic agents in an era of disease-modifying therapies","volume":"4","author":"Cummings","year":"2007","journal-title":"Rev. Neurol. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000122962","article-title":"Treatment options in Alzheimer\u2019s disease: Maximizing benefit, managing expectations","volume":"25","author":"Farlow","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-008-1394-2","article-title":"Methylthioninium chloride reverses cognitive deficits induced by scopolamine: Comparison with rivastigmine","volume":"202","author":"Deiana","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/gps.1949","article-title":"Improvement in behavioural symptoms in patients with moderate to severe Alzheimer\u2019s disease by memantine: A pooled data analysis","volume":"23","author":"Gauthier","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000200013","article-title":"Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer\u2019s Disease","volume":"27","author":"Grossberg","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer\u2019s disease: A pooled analysis of 3 studies","volume":"69","author":"Wilcock","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/gps.2384","article-title":"A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors","volume":"25","author":"Jones","year":"2009","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"92","DOI":"10.17925\/ENR.2012.07.02.92","article-title":"Combination drug therapy for the treatment of alzheimer\u2019s disease","volume":"7","author":"Linares","year":"2012","journal-title":"Eur. Neurol. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt7","article-title":"Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease","volume":"1","author":"Rountree","year":"2009","journal-title":"Alzheimers. Res. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jalz.2011.02.009","article-title":"Long-term progression of Alzheimer\u2019s disease in patients under antidementia drugs","volume":"7","author":"Andrieu","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:32:42Z","timestamp":1760362362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":137,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21093272"],"URL":"https:\/\/doi.org\/10.3390\/ijms21093272","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]}}}